Our Pipeline
Antithrombin Deficiency
Unmet Need
Hereditary antithrombin (AT) deficiency is associated with a significant risk of venous thromboembolism. Patients with this disorder frequently require long-term anticoagulation. Discontinuation of anticoagulation for childbirth or surgery may carry a substantial thrombotic risk. For this reason, replacement with plasma-derived AT concentrate is used when anticoagulation is interrupted.
Due to the inherent difficulty with glycosylation, there is no fully recombinant version of AT currently available – thus, patients must rely on plasma derived antithrombin with its short half-life, high cost, and risk of transmission of blood borne pathogens.
By leveraging our geCHO platform, we have developed a fully humanized, recombinant AT that precisely matches the native human glycoform. With a fully human recombinant AT in hand, we are currently optimizing the drug candidate to further extend the half-life.
Previous Attempts at Recombinant Antithrombin Could Not Match the Human-Derived Drug—Until Now
Learn More
Learn more about NeuImmune by downloading our most recent corporate presentation